{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:46:44Z","timestamp":1791809204965,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.radonc.2026.111754","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:46:12Z","timestamp":1788331572000},"page":"111754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-889X","authenticated-orcid":false,"given":"Cole","family":"Friedes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina N.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111754_b0005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2019.00543","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: where will the evidence lead?","volume":"9","author":"Al-Shafa","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0010","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111754_b0015","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0025","doi-asserted-by":"crossref","unstructured":"Francolini G, Gaetano Allegra A, Detti B, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). JCO. Published online September 21, 2023:JCO.23.0098doi:10.1200\/JCO.23.00985.","DOI":"10.1200\/JCO.23.00985"},{"key":"10.1016\/j.radonc.2026.111754_b0030","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111754_b0035","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: a phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0040","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2024.42.16_suppl.8506","article-title":"NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)","volume":"42","author":"Iyengar","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0045","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials: greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2026.111754_b0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2025.08.009","article-title":"Real-world endpoints in stereotactic body radiation therapy trials for oligoprogression: beyond progression-free survival and overall survival","volume":"125","author":"David","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111754_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218106","article-title":"Rethinking clinical trial endpoints for evaluating serially delivered \u2018strategic radiotherapy\u2019 in oligometastatic or oligoprogressive metastatic disease","volume":"635","author":"Chang","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.radonc.2026.111754_b0060","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1470-2045(26)00075-6","article-title":"Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC\u2013ESTRO OligoCare consortium","volume":"27","author":"Widder","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111754_b0070","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/JTO.0b013e318219aac5","article-title":"Radiological changes after stereotactic radiotherapy for stage I lung cancer","volume":"6","author":"Dahele","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0075","doi-asserted-by":"crossref","first-page":"S1614","DOI":"10.1016\/j.annonc.2025.09.086","article-title":"LBA72 NorthStar: a phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC)","volume":"36","author":"Elamin","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0080","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC","author":"Wang","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2026.111754_b0085","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0090","doi-asserted-by":"crossref","first-page":"S627","DOI":"10.1016\/S0167-8140(23)08702-9","article-title":"OC-0761 CORE - Standard of care +\/- stereotactic body radiotherapy for oligometastases - primary results","volume":"182","author":"Khoo","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0095","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR -mutated oligo-organ metastatic non\u2013small cell lung cancer treated with epidermal growth factor receptor\u2013tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111754_b0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for oligoprogressive cancers: results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111754_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","author":"Peng","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2468-1253(23)00316-3","article-title":"Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial","volume":"9","author":"Liu","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2026.111754_b0115","author":"Tsai","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111754_b0120","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ijrobp.2024.10.030","article-title":"Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): a multicenter, randomized phase 2 trial","volume":"121","author":"Reddy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111754_b0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2026.111754_b0135","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Niazi","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0140","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111754_b0145","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"JCO"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:07:46Z","timestamp":1791806866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026005931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"alternative-id":["S0167814026005931"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111754","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy trials","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111754"}}